HTG Molecular Diagnostics (NASDAQ:HTGM) has been assigned a $8.00 price objective by HC Wainwright in a research report issued to clients and investors on Monday. The brokerage presently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price objective suggests a potential upside of 111.08% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Tuesday, August 14th. ValuEngine downgraded shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, July 19th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $7.00 price target on shares of HTG Molecular Diagnostics in a research note on Friday, November 9th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $6.80.

Shares of NASDAQ HTGM opened at $3.79 on Monday. The company has a current ratio of 7.13, a quick ratio of 6.93 and a debt-to-equity ratio of 0.42. The company has a market cap of $104.01 million, a P/E ratio of -2.12 and a beta of 2.03. HTG Molecular Diagnostics has a 1 year low of $1.71 and a 1 year high of $5.83.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.01. The company had revenue of $4.71 million for the quarter, compared to the consensus estimate of $5.14 million. HTG Molecular Diagnostics had a negative net margin of 74.94% and a negative return on equity of 83.42%. Sell-side analysts anticipate that HTG Molecular Diagnostics will post -0.7 earnings per share for the current year.

A number of large investors have recently bought and sold shares of HTGM. Stonepine Capital Management LLC purchased a new position in HTG Molecular Diagnostics during the second quarter worth approximately $5,506,000. Putnam Investments LLC raised its stake in HTG Molecular Diagnostics by 31.4% during the second quarter. Putnam Investments LLC now owns 1,387,883 shares of the medical research company’s stock worth $4,524,000 after purchasing an additional 331,690 shares during the period. Russell Investments Group Ltd. purchased a new position in HTG Molecular Diagnostics during the third quarter worth approximately $1,089,000. Spark Investment Management LLC purchased a new position in HTG Molecular Diagnostics during the second quarter worth approximately $663,000. Finally, Granite Point Capital Management L.P. purchased a new position in HTG Molecular Diagnostics during the third quarter worth approximately $1,010,000. 50.49% of the stock is currently owned by institutional investors.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.

Recommended Story: Find a Trading Strategy That Works

Analyst Recommendations for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.